» Articles » PMID: 82995

The Recovery of Mice from Influenza A Virus Infection: Adoptive Transfer of Immunity with Influenza Virus-specific Cytotoxic T Lymphocytes Recognizing a Common Virion Antigen

Overview
Journal Scand J Immunol
Date 1978 Jan 1
PMID 82995
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Mice inoculated intranasally with infectious influenza virus of a given A strain were adoptively transferred 24 h later with preparations of secondary influenza virus-immune T cells generated either in vitro or entirely in vivo. The immune cells were raised during infection with homologous or heterologous A strain influenza viruses or with a type B virus. The greatest antiviral effect, measured by reduction in lung virus level of recipient mice, occurred if homologous viruses were used. Sharing of haemagglutinin specificity was shown to be important, but significant antiviral activity was still expressed if neither haemagglutinin nor neuraminidase antigenic specificities were shared. The antiviral effect was type-specific. Adoptive transfer of type A influenza immune T cells did not express antiviral activity against type B virus, and vice versa. On the basis of earlier work, the effector population in the transferred cells was cytotoxic T cells (Tc). Intranasal reinfection of mice with a heterologous type A virus sharing neither haemagglutinin nor neuraminidase antigenic specificity with the first infecting virus induced enhanced and earlier production of cross-reactive Tc against type A influenza viruses. This was paralleled by significantly lower virus levels in the lungs. The results of this work demonstrate heterotypic cell-mediated immunity in influenza virus infection in mice.

Citing Articles

Detrimental impact of allergic airway disease on live attenuated influenza vaccine.

Roy S, Williams C, Furuya Y Health Sci Rep. 2021; 4(3):e272.

PMID: 34250267 PMC: 8247940. DOI: 10.1002/hsr2.272.


Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus.

Lee S, Kang J, Chang J Clin Exp Vaccine Res. 2019; 8(1):54-63.

PMID: 30775351 PMC: 6369129. DOI: 10.7774/cevr.2019.8.1.54.


Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Fox A, Quinn K, Subbarao K Drugs. 2018; 78(13):1297-1308.

PMID: 30088204 DOI: 10.1007/s40265-018-0958-7.


Efficacy of recombinant measles virus expressing highly pathogenic avian influenza virus (HPAIV) antigen against HPAIV infection in monkeys.

Fujiyuki T, Horie R, Yoneda M, Kuraishi T, Yasui F, Kwon H Sci Rep. 2017; 7(1):12017.

PMID: 28931922 PMC: 5607339. DOI: 10.1038/s41598-017-08326-x.


Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity.

Powell T, Silk J, Sharps J, Fodor E, Townsend A J Virol. 2012; 86(24):13397-406.

PMID: 23015719 PMC: 3503098. DOI: 10.1128/JVI.01820-12.